Clinical trial
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not…
NCT00006043 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006043 |
|---|---|
| Title | Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin |
| Official title | Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Testicular Germ Cell Tumor |
| Intervention type | Drug |
| Interventions | temozolomide |
| Start date | Feb 1, 2000 |
| Primary completion | Nov 1, 2001 |
| Completion | Nov 1, 2001 |
| First posted | Apr 2, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: